Patents by Inventor Nobutaka Fujii

Nobutaka Fujii has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060264605
    Abstract: The present invention relates to a polypeptide represented by the formula: A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit-Cys-A7??(I) (wherein A1 represents a hydrogen atom or an arginine, lysine, ornithine, citrulline, alanine residue, etc.; A2 represents an aromatic amino acid residue; A3, A4 and A6 represent an arginine, lysine, ornithine, citrulline or alanine residue, A5 represents a tyrosine, phenylalanine, alanine, naphthylalanine or citrulline residue; A7 represents a lysine or arginine residue in which a carboxyl group may be amidated; X represents a D-ornithyl-proline, prolyl-D-ornithine, D-lysyl-proline residue, etc.; provided that either of A1, A3, A4, A5, A6 and A7 is an alanine residue, etc., or X is citrulline, etc.) or a salt thereof.
    Type: Application
    Filed: August 1, 2006
    Publication date: November 23, 2006
    Applicant: Biokine Therapeutics Ltd.
    Inventor: Nobutaka Fujii
  • Patent number: 7138488
    Abstract: Polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like).
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: November 21, 2006
    Assignee: Biokine Therapeutics Ltd.
    Inventor: Nobutaka Fujii
  • Publication number: 20060223847
    Abstract: The present invention provides an anti-coronavirus agent including as an active ingredient as exemplified by nelfinavir and salts thereof, an anti-SARS agent including the anti-coronavirus agent, and a method of treating SARS using the anti-SARS agent.
    Type: Application
    Filed: July 14, 2004
    Publication date: October 5, 2006
    Applicant: Arigen, Inc.
    Inventors: Nobutaka Fujii, Naoki Yamamoto
  • Patent number: 6855323
    Abstract: The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: February 15, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Artur Scherf, Louis H. Miller, Benoit Gamain, Dror I. Baruch, Pierre Buffet, Christine Scheidig, Jurg Gysin, Bruno Pouvelle, Nobutaka Fujii, Joseph Smith
  • Patent number: 6800611
    Abstract: The invention relates to metastin derivatives represented by the formula: X-AA1-AA2-AA3-AA4-Z (I), or a salt thereof, or a pro-drug thereof, which have cancer metastatis suppressing activity and cancer proliferation suppressing activity. The invention also relates to the use of these derivatives as drugs for preventing or treating cancers.
    Type: Grant
    Filed: January 6, 2003
    Date of Patent: October 5, 2004
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Nobutaka Fujii, Ryuichiro Doi, Shinya Oishi
  • Publication number: 20040142875
    Abstract: The invention relates to metastin derivatives represented by the formula: X-AA1-AA2-AA3-AA4-Z (I), or a salt thereof, or a pro-drug thereof, which have cancer metastatis suppressing activity and cancer proliferation suppressing activity. The invention also relates to the use of these derivatives as drugs for preventing or treating cancers.
    Type: Application
    Filed: January 6, 2003
    Publication date: July 22, 2004
    Inventors: Nobutaka Fujii, Ryuichiro Doi, Shinya Oishi
  • Publication number: 20040116655
    Abstract: Polypeptides of A1-Arg-A2-Cys-Tyr-A3-A4-X-A5-A6-Cit Cys-A7 (I) or their salts (wherein A1 is hydrogen or a residue of arginine, lysine, ornithine, citrulline, alanine, or the like; A2 is an aromatic amino acid residue; A3, A4 and A6 are each a residue of arginine, lysine, ornithine, citrulline, or alanine; A5 is a residue of tyrosine, phenylalanine, alanine, naphthylalanine, or citrulline; A7 is a lysine or arginine residue whose carboxyl group may be converted into amido; and X is a residue of D-ornithyl-proline, prolyl-D-ornithine, D-lysylproline, or the like, with the proviso that any one of A1, A3, A4, A5, A6 and A7 is a residue of alanine or the like or that X is citrulline or the like).
    Type: Application
    Filed: March 5, 2003
    Publication date: June 17, 2004
    Inventor: Nobutaka Fujii
  • Publication number: 20040062769
    Abstract: The present invention relates to the discovery of a var gene and corresponding protein that modulates adhesion of parasitized red blood cells to chondroitin sulfate A. Novel biological tools, prophylactics, therapeutics, diagnostics, and methods of use of the foregoing are also disclosed.
    Type: Application
    Filed: February 21, 2002
    Publication date: April 1, 2004
    Inventors: Arthur Scherf, Louis H. Miller, Benoit Gamain, Dror I. Baruch, Pierre Buffet, Christine Scheidig, Jurg Gysin, Bruno Pouvelle, Nobutaka Fujii, Joseph Smith
  • Patent number: 6545125
    Abstract: Compounds of the formula (1) or tautomers, stereoisomers or optical isomers thereof of the formula X—L—Y wherein X is paclitaxel or its derivative; L represents a linker having at least one functional group; and Y represents
    Type: Grant
    Filed: May 18, 2000
    Date of Patent: April 8, 2003
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventor: Nobutaka Fujii
  • Patent number: 5710128
    Abstract: A novel polypeptide sequence having the formula ##STR1## in which A.sub.1 is a hydrogen or at least one and no more than two amino acids selected from the group consisting of lysine and arginine,A.sub.2 is a tyrosine, phenylalanine or tryptophan residue,A.sub.3 is an arginine or lysine residue,A.sub.4 is at least one and no more than two amino acids selected from the group consisting of lysine and arginine, andA.sub.5 is an --OH or an NH.sub.2, is described.The polypeptide may be used in a pharmaceutical composition as an antimicrobial or antiviral agent, specifically as an anti-HIV agent.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: January 20, 1998
    Inventors: Nobutaka Fujii, Naoki Yamamoto, Akiyoshi Matsumoto, Michinori Waki
  • Patent number: 5571892
    Abstract: A novel polypeptide represented by the following formula (I) (SEQ. ID NO: 1) ##STR1## or a salt thereof, and an anti-HIV agent containing the same as an effective ingredient. According to this invention, there can be provided a novel polypeptide having an antiviral activity against human immunodeficiency virus (HIV), a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing the same as an effective ingredient.
    Type: Grant
    Filed: July 1, 1992
    Date of Patent: November 5, 1996
    Assignee: Seikagaku Kogyo Co., Ltd.
    Inventors: Nobutaka Fujii, Naoki Yamamoto
  • Patent number: 5449752
    Abstract: A novel polypeptide sequence having the formula ##STR1## in which A.sub.1 is a hydrogen or at least one and no more than two amino acids selected from the group consisting of lysine and arginine,A.sub.2 is a tyrosine, phenylalanine or tryptophan residue,A.sub.3 is an arginine or lysine residue,A.sub.4 is at least one and no more than two amino acids selected from the group consisting of lysine and arginine, andA.sub.5 is an --OH or an NH.sub.2, is described.The polypeptide may be used in a pharmaceutical composition as an antimicrobial or antiviral agent, specifically as an anti-HIV agent.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: September 12, 1995
    Assignee: Seikagaku Kogyo K.K.
    Inventors: Nobutaka Fujii, Naoki Yamamoto, Akiyoshi Matsumoto, Michinori Waki
  • Patent number: 5059679
    Abstract: The invention provides a method and reagent for the modification of polypeptides useful in experimental research in the area of genetic engineering starting from a polypeptide such as hCCK-33 in an unsulfated form which contains Tyr and Ser and/or Thr residues by first protecting the amino-groups in the starting polypeptide, masking the OH-groups in the Ser and/or Thr residues and selectively sulfating the OH-groups in the Tyr residues after deprotection.
    Type: Grant
    Filed: March 30, 1989
    Date of Patent: October 22, 1991
    Assignee: Shin-Etsu CHemical Co., Ltd.
    Inventors: Haruaki Yajima, Nobutaka Fujii, Shinya Kiyama
  • Patent number: 4950418
    Abstract: Reagent for removing protective groups employed in peptide synthesis comprises a combination of hard acid and soft base. The hard acid is trialkylsilyltrifluoromethanesulphonate R.sub.3 SiO.sub.3 SCF.sub.3 and the soft base is ether. The reagent provides high efficiency of deprotection and has a low tendency to cause side reaction.
    Type: Grant
    Filed: July 25, 1989
    Date of Patent: August 21, 1990
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Haruaki Yajima, Nobutaka Fujii, Gilberto M. A. Guterres, Tatsuhiko Honguu
  • Patent number: 4743677
    Abstract: A peptide represented by the following formula: ##STR1## wherein Y means a sulfur atom or methylene group, A stands for Asp or Asn, B denotes Val or Met and C is Asn or Ser, or a salt thereof.
    Type: Grant
    Filed: August 5, 1986
    Date of Patent: May 10, 1988
    Assignee: Toyo Jozo Co., Ltd.
    Inventors: Toshiharu Noda, Nobutaka Fujii, Kaoru Morita, Masayuki Hori